The role of hypothalamic microglia in the onset of insulin resistance and type 2 diabetes: a neuro-immune perspective
Historically, microglial activation has been associated with diseases of a neurodegenerative and neuroinflammatory nature. Some, like Alzheimer’s disease, Parkinson’s disease, and multiple system atrophy, have been explored extensively, while others pertaining to metabolism not so much. However, emerging evidence points to hypothalamic inflammation mediated by microglia as a driver of metabolic dysregulations, particularly insulin resistance and type 2 diabetes mellitus. Here, we explore this connection further and examine pathways that underlie this relationship, including the IKKβ/NF-κβ, IRS-1/PI3K/Akt, mTOR-S6 Kinase, JAK/STAT, and PPAR-γ signaling pathways. We also investigate the role of non-coding RNAs, namely microRNAs and long non-coding RNAs, in insulin resistance related to neuroinflammation and their diagnostic and therapeutic potential. Finally, we explore therapeutics further, searching for both pharmacological and non-pharmacological interventions that can help mitigate microglial activation.
History
Data Availability Statement
Not applicable.Comments
The original article is available at https://www.mdpi.com/Published Citation
Darwish R, et al. The role of hypothalamic microglia in the onset of insulin resistance and type 2 diabetes: a neuro-immune perspective. Int J Mol Sci. 2024;25(23):13169.Publication Date
7 December 2024External DOI
PubMed ID
39684879Department/Unit
- RCSI Bahrain
Publisher
MDPIVersion
- Published Version (Version of Record)